The Association between Urinary Glucose and Renal Uric Acid Excretion in Non-diabetic Patients with Stage 1-2 Chronic Kidney Disease

References

• Maahs DM, Caramori L, Cherney DZ, et al. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep. 2013;13(4):550–559.
   PubMed Web of Science ®Google Scholar
• Ficociello LH, Rosolowsky ET, Niewczas MA, et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care. 2010;33(6):1337–1343.
   PubMed Web of Science ®Google Scholar
• Jalal DI, Rivard CJ, Johnson RJ, et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the coronary artery calcification in type 1 diabetes study. Nephrol Dialysis Transplant. 2010;25(6):1865–1869.
   PubMed Web of Science ®Google Scholar
• Zoppini G, Targher G, Chonchol M, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2012;35(1):99–104.
   PubMed Web of Science ®Google Scholar
• Altemtam N, Russell J, El Nahas M. A study of the natural history of diabetic kidney disease (DKD). Nephrol Dialysis Transplant. 2012;27:1847–1854.
   PubMed Web of Science ®Google Scholar
• Bjornstad P, Snell-Bergeon JK, McFann K, et al. Serum uric acid and insulin sensitivity in adolescents and adults with and without type 1 diabetes. J Diabetes Complications. 2014;28(3):298–304.
   PubMed Web of Science ®Google Scholar
• Vuorinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994;78:25–29.
   PubMed Web of Science ®Google Scholar
• Muscelli E, Natali A, Bianchi S, et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens. 1996;9(8):746–752.
   PubMed Web of Science ®Google Scholar
• Quinones Galvan A, Natali A, Baldi S, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995;268(1 Pt 1):E1–5.
   PubMed Web of Science ®Google Scholar
• Toyoki D, Shibata S, Kuribayashi-Okuma E, et al. Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2. Am J Physiol Renal Physiol. 2017;313(3):F826–F834.
   PubMed Web of Science ®Google Scholar
• Spoto B, Pisano A, Zoccali C. Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol Renal Physiol. 2016;311:F1087–F1108.
   PubMed Web of Science ®Google Scholar
• Mallat SG, Al Kattar S, Tanios BY, Jurjus A. Hyperuricemia, hypertension, and chronic kidney disease: an emerging association. Curr Hypertens Rep. 2016;18:74.
   PubMed Web of Science ®Google Scholar
• Lv Q, Meng XF, He FF, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PloS One. 2013;8(2):e56864.
   PubMed Web of Science ®Google Scholar
• Jia Z, Zhang X, Kang S, Wu Y. Serum uric acid levels and incidence of impaired fasting glucose and type 2 diabetes mellitus: a meta-analysis of cohort studies. Diabetes Res Clin Pract. 2013;101:88–96.
   PubMed Web of Science ®Google Scholar
• Krishnan E, Akhras KS, Sharma H, et al. Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. QJM. 2013;106(8):721–729.
   PubMed Web of Science ®Google Scholar
• Lytvyn Y, Skrtic M, Yang GK, Yip PM, Perkins BA, Cherney DZ. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2015;308:F77–83.
   PubMed Web of Science ®Google Scholar
• Hyndman D, Liu S, Miner JN. Urate handling in the human body. Curr Rheumatol Rep. 2016;18:34.
   PubMed Web of Science ®Google Scholar
• Li F, Guo H, Zou J, et al. The association of urinary sodium and potassium with renal uric acid excretion in patients with chronic kidney disease. Kidney Blood Press Res. 2018;43(4):1310–1321.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606–617.
   Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458–462.
   PubMed Web of Science ®Google Scholar
• Novikov A, Fu Y, Huang W, et al. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. Am J Physiol Renal Physiol. 2019;316(1):F173–F185.
   PubMed Web of Science ®Google Scholar
• Wang IK, Tsai TH, Hung YC, et al. Increased risk of new-onset type 2 diabetes in people with chronic kidney disease. Int Urol Nephrol. 2019;51(4):707–712.
   PubMed Web of Science ®Google Scholar
• Lin CY, Hsieh MC, Kor CT, Hsieh YP. Association and risk factors of chronic kidney disease and incident diabetes: a nationwide population-based cohort study. Diabetologia. 2019;62:438–447.
   PubMed Web of Science ®Google Scholar
• Edwards A, Auberson M, Ramakrishnan SK, Bonny O. A model of uric acid transport in the rat proximal tubule. Am J Physiol Renal Physiol. 2019;316:F934–F947.
   PubMed Web of Science ®Google Scholar
• Hung CC, Lin HY, Lee JJ, et al. Glycosuria and renal outcomes in patients with nondiabetic advanced chronic kidney disease. Sci Rep. 2016;6:39372.
   PubMed Web of Science ®Google Scholar
• Guan H, Zheng Y, Zhou X, et al. Efficacy of different urinary uric acid indicators in patients with chronic kidney disease. BMC Nephrol. 2020;21(1):290.
   PubMed Web of Science ®Google Scholar
• Stevens PE, Levin A. Kidney disease: improving global outcomes chronic kidney disease guideline development work group M. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–830.
   PubMed Web of Science ®Google Scholar
• Lytvyn Y, Perkins BA, Cherney DZ. Uric acid as a biomarker and a therapeutic target in diabetes. Can J Diabetes. 2015;39:239–246.
   PubMed Web of Science ®Google Scholar
• Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study. Ann Intern Med. 1999;131:7–13.
   PubMed Web of Science ®Google Scholar
• Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: atherosclerosis risk in communities (ARIC) study. Ann Epidemiol. 2000;10:136–143.
   PubMed Web of Science ®Google Scholar
• Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F; Group MS. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The mild to moderate kidney disease (MMKD) study. Exp Gerontol. 2008;43(4):347–352.
   PubMed Web of Science ®Google Scholar
• Golembiewska E, Ciechanowski K, Safranow K, Kedzierska K, Kabat-Koperska J. Renal handling of uric acid in patients with type 1 diabetes in relation to glycemic control. Arch Med Res. 2005;36:32–35.
   PubMed Web of Science ®Google Scholar
• Skeith MD, Healey LA, Cutler RE. Urate excretion during mannitol and glucose diuresis. J Lab Clin Med. 1967;70:213–220.
   PubMed Web of Science ®Google Scholar
• Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol. 2015;77:323–345.
   PubMed Web of Science ®Google Scholar
• Bjornstad P, Lanaspa MA, Ishimoto T, et al. Fructose and uric acid in diabetic nephropathy. Diabetologia. 2015;58(9):1993–2002.
   PubMed Web of Science ®Google Scholar
• List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int Suppl. 2011;79(120):S20–27.
   Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int. 2014;86(5):1057–1058.
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44:375–393.
   PubMed Web of Science ®Google Scholar
• Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35(7):391–404.
   PubMed Web of Science ®Google Scholar
• Scholl-Burgi S, Santer R, Ehrich JH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dialysis Transplant. 2004;19:2394–2396.
   PubMed Web of Science ®Google Scholar
• Calado J, Santer R, Rueff J. Effect of kidney disease on glucose handling (including genetic defects). Kidney Int Suppl. 2011;79(120):S7–13.
   Google Scholar
• Magen D, Sprecher E, Zelikovic I, Skorecki K. A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int. 2005;67:34–41.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587–597.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499–508.
   PubMed Web of Science ®Google Scholar